Pfizer’s Troxyca ER Opioid Combo Faces Intravenous Abuse Concerns
This article was originally published in The Pink Sheet Daily
More oxycodone was extracted from the combination product, potentially defeating the opioid-blunting effects of the naltrexone component and creating a hurdle to an abuse-deterrent claim.
You may also be interested in...
Restrictive REMS Is Least Favored Path For Opioid Prescriber Education
FDA advisory committee's preferred approaches – linking mandatory training to DEA registration or state medical board licensing – are outside agency's existing regulatory authority.
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
US FDA Program Streamlining COVID-19 Treatment Development Still Working As Emergency Ends
Any program changes would not occur until after a thorough assessment, the agency said.